Vivos Therapeutics Inc (VVOS)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $3.29M
Last updated: Nov 17, 2026 at 11:05 AM ET
Vivos Therapeutics Inc (VVOS) Earnings: Report Dates and Results
Vivos Therapeutics (VVOS) is expected to report earnings on Nov 17, 2026. In the quarter ended Jun 30, 2026, Vivos Therapeutics reported EPS of -$0.31, above the -$0.42 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
VVOS has an expected report date of Nov 17, 2026.
VVOS Earnings Call
The latest VVOS earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 23 quarters below that had an estimate, VVOS beat 7 and missed 16. Revenue for the quarter ended Jun 30, 2026 was $5.15M, up 34.8% from $3.82M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$0.31 | -$0.42 | -$0.54 - -$0.29 | +26.19% | Beat | N/A | 4 | 0 up, 0 down | Aug 14, 2026 | $5.15M |
| Mar 31, 2026 | -$0.52 | -$0.45 | -$0.49 - -$0.40 | -15.56% | Miss | N/A | 3 | 0 up, 0 down | Apr 15, 2026 | $5.14M |
| Dec 31, 2025 | -$0.58 | -$0.50 | -$0.53 - -$0.46 | -17.17% | Miss | N/A | 3 | 0 up, 0 down | Mar 26, 2026 | $3.82M |
| Sep 30, 2025 | -$0.49 | -$0.51 | -$0.55 - -$0.48 | +3.92% | Beat | N/A | 3 | 0 up, 1 down | Nov 19, 2025 | $6.78M |
| Jun 30, 2025 | -$0.55 | -$0.38 | -$0.38 - -$0.38 | -44.74% | Miss | N/A | 1 | 0 up, 1 down | Aug 19, 2025 | $3.82M |
| Mar 31, 2025 | -$0.45 | -$0.44 | -$0.44 - -$0.36 | -2.27% | Miss | N/A | 2 | 0 up, 1 down | May 15, 2025 | $3.02M |
| Dec 31, 2024 | -$0.28 | -$0.43 | -$0.43 - -$0.43 | +34.88% | Beat | N/A | 1 | 1 up, 0 down | Mar 31, 2025 | $3.70M |
| Sep 30, 2024 | -$0.40 | -$0.70 | -$0.70 - -$0.70 | +42.86% | Beat | N/A | 1 | 1 up, 0 down | Nov 14, 2024 | $3.86M |
| Jun 30, 2024 | -$0.60 | -$1.05 | -$1.05 - -$1.05 | +42.86% | Beat | N/A | 1 | 0 up, 0 down | Aug 14, 2024 | $4.05M |
| Mar 31, 2024 | -$1.63 | -$1.16 | -$1.19 - -$1.16 | -40.52% | Miss | -209.4% | 2 | 0 up, 0 down | May 14, 2024 | $3.42M |
| Dec 31, 2023 | -$3.05 | -$1.90 | -$2.06 - -$1.75 | -60.53% | Miss | N/A | 2 | 0 up, 0 down | Mar 28, 2024 | $3.25M |
| Sep 30, 2023 | -$3.08 | -$3.00 | -$3.25 - -$3.00 | -2.67% | Miss | N/A | 2 | 0 up, 0 down | Nov 14, 2023 | $3.30M |
| Jun 30, 2023 | -$3.89 | -$3.50 | -$3.75 - -$3.50 | -11.14% | Miss | N/A | 2 | 0 up, 0 down | Aug 16, 2023 | $3.40M |
| Mar 31, 2023 | $1.49 | -$4.75 | -$4.75 - -$4.25 | +131.37% | Beat | N/A | 2 | 0 up, 0 down | Jun 8, 2023 | $3.86M |
| Dec 31, 2022 | -$0.20 | -$0.22 | -$0.22 - -$0.22 | +9.09% | Beat | N/A | 2 | 0 up, 0 down | Mar 30, 2023 | $3.95M |
| Sep 30, 2022 | -$6.50 | -$6.25 | N/A | -4.00% | Miss | N/A | N/A | 0 up, 0 down | Dec 20, 2022 | $4.25M |
| Jun 30, 2022 | -$0.28 | -$0.25 | N/A | -12.00% | Miss | N/A | N/A | 0 up, 0 down | Aug 23, 2022 | $4.18M |
| Mar 31, 2022 | -$8.01 | -$6.50 | -$7.25 - -$5.75 | -23.23% | Miss | N/A | 2 | 0 up, 0 down | May 16, 2022 | $3.64M |
| Dec 31, 2021 | -$0.34 | -$0.25 | -$0.27 - -$0.23 | -36.00% | Miss | N/A | 2 | N/A | Mar 31, 2022 | $4.39M |
| Sep 30, 2021 | -$6.50 | -$4.62 | -$5.25 - -$4.00 | -40.69% | Miss | N/A | 2 | N/A | Nov 15, 2021 | $4.55M |
| Jun 30, 2021 | -$4.75 | -$4.50 | -$5.00 - -$4.00 | -5.56% | Miss | N/A | 2 | N/A | Aug 12, 2021 | $4.50M |
| Mar 31, 2021 | -$4.75 | -$4.25 | -$4.25 - -$4.25 | -11.76% | Miss | N/A | 2 | N/A | May 17, 2021 | $3.45M |
| Dec 31, 2020 | -$0.88 | -$0.16 | -$0.21 - -$0.12 | -450.00% | Miss | N/A | 2 | N/A | Mar 25, 2021 | $16.37M |
| Sep 30, 2020 | -$0.23 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 14, 2020 | $3.29M |
| Jun 30, 2020 | -$0.16 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2020 | $3.27M |
| Mar 31, 2020 | -$0.18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2020 | $3.20M |
| Dec 31, 2019 | -$0.18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2020 | $3.06M |
| Jun 30, 2019 | -$0.27 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2019 | $2.51M |
| Mar 31, 2019 | -$0.23 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2019 | $2.51M |
| Dec 31, 2018 | -$0.23 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2019 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$2.07, after -$2.91 the year before. It was -$0.23 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$2.07 | N/A |
| Dec 31, 2024 | -$2.91 | N/A |
| Dec 31, 2023 | -$8.53 | N/A |
| Dec 31, 2022 | -$14.99 | N/A |
| Dec 31, 2021 | -$16.34 | N/A |
| Dec 31, 2020 | -$1.45 | N/A |
| Dec 31, 2019 | -$0.67 | N/A |
| Dec 31, 2018 | -$0.23 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 4,900 words across 4 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 4,904 | 4 | |
| 2026Q1 | Mar 31, 2026 | 4,035 | 4 | |
| 2025Q4 | Dec 31, 2025 | 6,702 | 5 | |
| 2025Q3 | Sep 30, 2025 | 5,030 | 5 | |
| 2025Q2 | Jun 30, 2025 | 5,068 | 5 | |
| 2025Q1 | Mar 31, 2025 | 4,766 | 5 | |
| 2024Q3 | Sep 30, 2024 | 7,502 | 6 | |
| 2024Q2 | Jun 30, 2024 | 4,954 | 6 |
2026Q2 Earnings Call
Opening remarks
Bradford K. Amman Principal Accounting Officer and former CFO Thank you, Ludy. Hello, everyone, and welcome to our conference call. A copy of our earnings press release is available on the Investor Relations section of our website at www.vivos.com. With me on the call today is Kirk Huntsman, Vivos' Chairman and Chief Executive Officer; and Roman Franklin, Vivos' Chief Financial Officer and Principal Financial Officer. Today, we will review the financial results of the second quarter of 2026 as well as more recent developments and Vivos' plans for the rest of the year 2026 and beyond. Following these formal remarks, we will be happy to take questions. I would also like to remind everyone that today's call will contain certain forward-looking statements from our management made within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities and Exchange Act of 1934 as amended, concerning future events. Words such as aim, may, could, should, projects, expects, intends, plans, believes, anticipates, hopes, estimates, goal and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve significant known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant risks, uncertainties and contingencies, many of which are beyond the company's control. Actual results, including, without limitation, the results of Vivos' growth strategies, operational plans, including sales, marketing, distribution, medical sleep provider, acquisition and integration, research and development, regulatory initiatives, cost savings plans and plans to generate revenue as well as future potential results of operations or operating metrics such as the potential for Vivos to achieve future positive cash flows or profitability and other matters to be addressed by Vivos' management in this conference call may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in other disclosures contained in Vivos' filings with the Securities and Exchange Commission, including the risk factors and other disclosures in our Form 10-K for the year ended December 31, 2025, and our other filings with the SEC including our second quarter 10-Q filed with the SEC today, all of which are, or will be accessible on the Investor Relations section of the Vivos website as well as the SEC's website. Except to the extent required by law, Vivos assumes no obligation to update statements as circumstances change. Finally, please be aware that the U.S. Food and Drug Administration has given certain specific Vivos appliances 510(k) clearance to treat mild to severe OSA in adults.
Frequently Asked Questions About VVOS
When is Vivos Therapeutics's next earnings date?
Vivos Therapeutics's next earnings report is expected for Nov 17, 2026.
Did VVOS beat earnings estimates last quarter?
Yes. Vivos Therapeutics reported EPS of -$0.31 for the quarter ended Jun 30, 2026, above the -$0.42 estimate, a 26.19% surprise.
What EPS do analysts expect from VVOS next quarter?
The consensus EPS estimate for Vivos Therapeutics for the quarter ended Sep 30, 2026 is -$0.32 from 3 analysts, with estimates from -$0.54 to -$0.12.
How often does VVOS beat earnings estimates?
Vivos Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +3.51%.
VVOS pages: Overview, Earnings, Forecast, Financials, Competitors